3-hydroxykynurenine has been researched along with Idiopathic Parkinson Disease in 7 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "The kynurenine (KYN) pathway plays an important role in degrading molecules responsible for oxidative stress in the central nervous system (CNS), but can also have neurotoxic effects." | 1.56 | Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. ( Iwaoka, K; Kato, K; Maeda, T; Otsuka, C; Takahashi, K; Terayama, Y; Yamahara, K, 2020) |
| "In untreated patients with Parkinson's disease (PD), the total (free and conjugated) serotonin (5-HT) and dopamine (DA) concentrations in the cerebrospinal fluid decreased significantly." | 1.29 | Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. ( Abe, T; Hamato, H; Takahashi, J; Takahashi, S; Tohgi, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Iwaoka, K | 1 |
| Otsuka, C | 1 |
| Maeda, T | 1 |
| Yamahara, K | 1 |
| Kato, K | 1 |
| Takahashi, K | 2 |
| Terayama, Y | 1 |
| Robertson, DS | 1 |
| Lewitt, PA | 1 |
| Li, J | 1 |
| Lu, M | 1 |
| Beach, TG | 1 |
| Adler, CH | 1 |
| Guo, L | 1 |
| Amara, AW | 1 |
| Standaert, DG | 1 |
| Tohgi, H | 2 |
| Abe, T | 2 |
| Takahashi, S | 2 |
| Takahashi, J | 2 |
| Hamato, H | 2 |
1 review available for 3-hydroxykynurenine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
6 other studies available for 3-hydroxykynurenine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease.
Topics: Aged; Case-Control Studies; Cytokines; Female; Humans; Inflammation; Interferon-gamma; Interleukin-1 | 2020 |
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Glutathione; Humans; Kynurenine; Male; Mass Spec | 2013 |
Metabolomics and the search for biomarkers in Parkinson's disease.
Topics: Female; Humans; Kynurenine; Male; Oxidative Stress; Parkinson Disease | 2013 |
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration.
Topics: Aged; Dopamine; Humans; Hydroxyindoleacetic Acid; Kynurenine; Levodopa; Middle Aged; Parkinson Disea | 1993 |
Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms.
Topics: 5-Hydroxytryptophan; Humans; Hydroxyindoleacetic Acid; Kynurenine; Middle Aged; Parkinson Disease; R | 1993 |